Skip to main content

Evrysdi Side Effects

Generic name: risdiplam

Medically reviewed by Drugs.com. Last updated on Oct 19, 2023.

Note: This document contains side effect information about risdiplam. Some dosage forms listed on this page may not apply to the brand name Evrysdi.

Applies to risdiplam: oral powder for solution.

Serious side effects of Evrysdi

Along with its needed effects, risdiplam (the active ingredient contained in Evrysdi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking risdiplam:

More common

Less common

Other side effects of Evrysdi

Some side effects of risdiplam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to risdiplam: oral powder for reconstitution.

General

The most frequently reported side effects included fever, diarrhea, headache, and rash. Additionally, among patients with infantile-onset spinal muscular atrophy, upper respiratory tract infection, lower respiratory tract infection, constipation, vomiting, and cough were reported.[Ref]

Dermatologic

Very common (10% or more): Rash (up to 17%)

Common (1% to 10%): Eczema

Postmarketing reports: Cutaneous vasculitis

Rash included dermatitis, rash, erythema, maculo-papular rash, erythematous rash, popular rash, allergic dermatitis, acneiform dermatitis, and folliculitis.

Cutaneous vasculitis was identified during post-marketing experience.

Endocrine

Common (1% to 10%): Cryptorchism

Gastrointestinal

Very common (10% or more): Constipation (up to 25%), diarrhea (up to 17%), vomiting (up to 17%)

Common (1% to 10%): Mouth and aphthous ulcers, gastroesophageal reflux disease, gastroenteritis, nausea, upper abdominal pain

Genitourinary

Common (1% to 10%): Urinary tract infection

Urinary tract infection included urinary tract infection and cystitis.

Musculoskeletal

Common (1% to 10%): Arthralgia, joint dislocation

Nervous system

Very common (10% or more): Headache (20%)

Other

Very common (10% or more): Pyrexia (up to 54%), teething (up to 13%)

Common (1% to 10%): Ear infection

Pyrexia included fever and hyperpyrexia.

Respiratory

Very common (10% or more): Upper respiratory tract infection (up to 82%), pneumonia (up to 40%), cough (12.9%), bronchitis (up to 11%)

Common (1% to 10%): Respiratory failure, respiratory distress, acute respiratory failure, atelectasis

Frequency not reported: Lower respiratory tract infection

Upper respiratory tract infections included nasopharyngitis, respiratory tract infection, rhinitis, influenza, pharyngitis, viral respiratory tract infection, upper respiratory tract infection (bacterial and viral), and COVID-19.

Lower respiratory tract infection included pneumonia and bronchitis.

Frequently asked questions

References

1. (2020) "Product Information. Evrysdi (risdiplam)." Genentech

2. (2024) "Product Information. Evrysdi (risdiplam)." Genentech

3. (2023) "Product Information. Evrysdi (risdiplam)." Roche Products Pty Ltd

4. (2023) "Product Information. Evrysdi (risdiplam)." Roche Products Ltd

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.